Group items tagged

The Royal Pharmaceutical Society (RPS) has published its new 'Core Advanced Pharmacist Curriculum' to enable professional development towards advanced pharmacist practice. This follows an intensive programme of work undertaken in collaboration with a wide range of UK stakeholders, the society said today (June 27) in a statement. The Curriculum will equip pharmacists with advanced leadership, education, and research capabilities which are essential to support, lead and advance the profession through transformative change so it continues to meet evolving patient and service requirements. The RPS Core Advanced Curriculum provides the blueprint to develop such individuals by articulating a UK entry-level standard to advanced pharmacist practice, relevant to all patient-focussed pharmacist roles and aligned to multi-professional definitions of advanced practice. This curriculum completes the core RPS post-registration curricula, creating a seamless post-registration professional development continuum modelled around five common domains- Person-centred care and collaboration; Professional practice; Leadership and management; Education; and Research.

Many community pharmacists are keen to pursue independent prescribing training, but the lack of access to placements, supervisors, and adequate financial support remains a challenge. In a significant development, the government has announced the nationwide expansion of the 'Teach and Treat' clinics pilot to assist pharmacists in becoming independent prescribers (IPs). Initially piloted in the South West, this initiative allowed many community pharmacists to gain practice-based learning, with supervision from an experienced prescriber called a Designated Prescribing Practitioner (DPP). This expansion was confirmed in the government's response to the House of Commons Health and Social Care Committee (HSCC) pharmacy inquiry, published on 10 January 2025. The initiative is described as "an effective way to create designated DPP capacity and grow the number of pharmacist independent prescribers." The expansion of the Teach and Treat clinics will be facilitated through the Pharmacy Integration Fund in 2024-25.

Dementia and Alzheimer's disease remained the leading cause of death in England and Wales in 2023, maintaining the pre-pandemic trend, according to the latest data from the Office for National Statistics (ONS). The figures reveal that there were 66,876 deaths with an underlying cause of dementia and Alzheimer's disease, accounting for 11.6% of all deaths registered that year. In response to this growing health concern, Luye Pharma is hosting a free special educational webinar on 6 November 2024 (timing: 18:30 - 20:00) for healthcare professionals. Titled "Treating Dementia in 2024: Optimising Pathways Between Primary and Secondary Care," the online session will focus on addressing the ever-increasing challenges in dementia treatment and how to optimise pathways between primary and secondary care. The webinar will feature expert speakers from the field of dementia care, including Dr. Jill Rasmussen, Primary Care Specialist in dementia, mental health, and intellectual disabilities; Delia Bashara, Consultant Pharmacist for the Mental Health of Older Adults and Dementia at South London and Maudsley NHS Foundation Trust; and Khaleel Loonat, Senior Clinical Pharmacist and Advanced Clinical Practitioner.